NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved TherapiesPRNewsWire • 12/29/21
NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19GlobeNewsWire • 12/14/21
NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine TrialsGlobeNewsWire • 12/09/21
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other RegionsGlobeNewsWire • 12/06/21
NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered RemdesivirGlobeNewsWire • 11/29/21
NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological ResearchGlobeNewsWire • 11/26/21
NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/16/21
NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial ResultsGlobeNewsWire • 11/16/21
NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel ConferenceGlobeNewsWire • 11/12/21
NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing InformationGlobeNewsWire • 11/11/21
NRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021GlobeNewsWire • 11/09/21